

Antimicrobial Activity Zinc Oxide ZnO Nanoparticles Against Biofilm Formation of Uropathogenic E. coli

Jinan Mohammed Hasan^{1*}, Zainab Zamel Khalafi¹ and Saif Talib Jasim²

¹ Biology department, College of Science, Baghdad University, Iraq

² Ministry of Education

Abstract— UroPathogenic *Escherichia coli* (UPEC) are the main reason of urinary tract infections (UTIs) that consider as among the most prevalent pathological states in both community and hospital settings. Twenty isolates of *E. coli* were isolated from 50 urine samples obtained from different Hospitals at Baghdad, Iraq from patients with UTIs at (40%) isolation percentage. These isolates were diagnosed by biochemical tests, and confirmed by Analytic Profile Index (API 20E) as *E. coli* isolates. They were detected for the ability they had to biofilm formation by microtiter plate method. Five of them were considered as a biofilm former. These isolates were tested for the effect of ZnO on their biofilm formation pre-mature and mature biofilm by using 4 concentrations (500, 250, 125 and 62.5µg/ml). The results showed that all concentrations of ZnONPs showd antibiofilm activity against pre mature and post mature biofilm. The best effect was recorded against pre mature biofilm.

Index Terms— *E. coli*, UTI, Uropathogenic *E. coli*, Biofilm, nanoparticles, ZnO.

I. INTRODUCTION

This In 1885 *Escherichia coli* were at first isolated from infants' feces by German pediatrician Theodor Escherich (1857–1911) (1,2). *E. coli* belong to family Enterobacteriaceae (3). It is a Gram-negative bacterium, non-spore-forming and usually motile by peritrichous flagella (3,4). The genus *Escherichia* commonly resides in the lower gut of warm-blooded animals, environment, and foods (5,6). It is oxidase-negative, grows using simple carbon sources, citrate-negative, methyl red-positive, Voges–Proskauer-negative and colonies are display a green sheen selective media as eosin methylene blue (EMB) (2).

Urinary tract infections (UTIs) are one of main causes that lead to morbidity affecting 150 million people each year worldwide (7). *E. coli* is the most frequent cause of acute urinary tract infections, neonatal meningitis, , abscesses in a various organ systems, urinary tract sepsis, acute enteritis in humans and animals, it is a general cause of haemorrhagic colitis often referred to as 'bloody diarrhoea' and commonly linked to a dysentery-like disease affecting humans known as 'traveller's diarrhoea' (8,9). Also it is one of the most frequent hospital-acquired pathogens which can cause abdominal infections and bloodstream infections (BSI) (10). Uropathogenic *E. coli* (UPEC) is responsible for 80-90% of community- acquired and

30-50% of hospital acquired UTIs. It is the primary cause of UTIs (11,12). A growing threat to global health is the emergence and rapid spread of carbapenem and extended-spectrum cephalosporin resistance in Enterobacteriaceae. Furthermore, the prevalence of antibiotics resistance *E. coli* is rising, posing a serious threat to human health worldwide (13,14).

Besides being the primary causative agent for recurrent UTIs, the infectivity associated with indwelling medical device-related is also caused by *E. coli* biofilm (15). It is biofilm made up of a bacterial colony embedded in a matrix of extracellular polymeric substances (EPS). It shields the microorganism from environmental conditions which could otherwise lead to infection and this diversity biofilm's structural components are exacerbated by the emergence of antibiotics resistance, making it more difficult to eradicate (16,17). Biofilms offer a setting that resistance to antibiotic penetration and facilitate the horizontal transfer of virulence genes, thereby promoting the development of Multidrug-resistant organisms (MDRO) (18,19). The capacity of UPEC to form biofilms makes use of various virulence factors determine its ability to invade, grow, ascend and persist in the uroepithelium (20,21).

The need for high doses of antibiotics, which frequently result in intolerable toxicity, is increased due to the increased of resistance to antimicrobial agents. As a result, researchers looked for different approach for treating bacterial infections and developed nanostructures as novel antimicrobial agents (22,23,24). The prices mechanism of actions of nanoparticles are still unclear, but they may be depends on variety of factors including bacterial species, concentrations, surface modifications, compositions, and intrinsic compositions of the particles. Of all of the metal oxide nanoparticles, Zinc oxide nanoparticle (ZnO-NP) were found as the most toxic against *E. coli*. Its produce reactive oxygen species that kill the bacteria by disrupts membrane integrity (25,26).

The range of cellular target of conventionally antimicrobial agents is limited and their effectiveness against biofilm is also limited, this highlights the necessity for investigated alternative therapies such as nanomaterial for efficient drug delivery to prevent the growth of biofilm (27,28). This study aimed to: isolation and diagnosis of *E. coli* from patients suffering from UTI, detection the isolates ability to form biofilm by microtiter plate method and detection the ability of ZnO-NP to effect on mature and premature UPEC biofilm.

II. MATERIALS AND METHODS

A. Specimens Collections and Isolates Diagnosis

Fifteen urine specimens were collected in sterilized containers from three hospitals in Baghdad, Al-Imam Ali hospital, Ibn Al-baladi hospital, and Fatema Al-Zahraa hospital. The samples first have been directly transferred to the lab for examination and diagnosis. All the specimens were cultured onto the MacConkey and EMB agar by streak plate method to observe the colony morphology. The organisms exhibiting the distinctive colonial morphology was of *E. coli* was repeatedly subculture onto EMB agar, incubated for 24 hours at 37°C in order to obtained a pure culture with homogenous colonies (29). Then, the suspected colonies were transferred to culture on blood agar for hemolysis activity, Triple Sugar iron agar (TSI) and MR-VP for sugar fermentation, Urea agar for urease production, Peptone water for indole test and Simome citrate for citrate utilization test (Himedia/ India) tubes for 24h incubated at 37C(30).

B. Detection of Biofilm Formation

The biofilm formation was bacterial isolates was detecting by microtiter plate method (31). All the obtained bacterial isolates from the previous stage were cultured in Brain Heart Infusion broth (BHI) containing 1% glucose, 96-well polystyrene tissue culture plates was used and then incubated at a temperature of 37C for. Washed 3 times by the DW, and the adhering cells in the wells have been fixed with 200µl of the absolute methanol for 20min; the plates have been emptied and then left overnight to dry. Adhering cells have been stained of with 0.1% crystal violet in a 200µl volume for 15 min, and the excess stain has been descanted and left for drying at room temperature overnight. 200µl of 96% of the ethanol in each one of the wells were used for dye fixation. Plate has been read at 490nm by spectrophotometer. Each isolate was carried out in triplicates and the results have been compared with absorbance of the wells that contain sterile BHI broth as the control.

C. Preparation of ZnO NPs Suspension

The preparation of nanoparticles was done in accordance to (32); After adding 100 ml of the ZnO to 10ml of the sterile DW, thoroughly shake the mixture. The suspension solution was subjected for 30 min of ultra-sound (40 kHz), followed by autoclaved at 121C for 20min and cooling period to room temperature.

D. Detecting Anti-biofilm Activities of ZnO Against Bacterial Isolates

The previously mentioned procedure in biofilm formation was followed but with various concentration levels of the ZnO (500, 250, 125 and 62.5µg/ml). NPs which have been added with the bacterial suspension to the wells, as triplicate for every value of the concentration, and then the plate was incubated for 24hr at 37C, after the period of incubation, and have been washed, stained, and read OD at 490nm.

E. Statistical Analysis

The program SAS (2018) (33) was utilize to ascertain the impact of variant factors in the study parameter. In this study a significant comparison between means was made using the Least significant difference –LSD test (Analysis of Variation-ANOVA).

III. RESULTS

A. Bacterial Isolates

Twenty *E. coli* isolates from 50 urine specimens were identified by using culture media and biochemical test as shown in the table (1) in (40%) isolation percentage. *E. coli* colonies on MacConkey agar showed up a tiny, pink colonies (Lactose fermentor), but colonies on EMB agar showed up a green metallic sheen. Colonies that tested positive for Lactose- and indole and negative for citrate utilization test were presumptively identified as *E. coli*.

Table (1): Results of biochemical test of *E. coli* isolates


No.	Biochemical test and media	Result
1	MacConkey agar	Small, smooth pink colonies
2	Eosin Methylene Blue (EMB)	Green metallic Sheen
3	Triple sugar iron agar (TSI)	A/A + (gas) – (no H ₂ S)
4	Urease test	-ve
5	Indole test	+ve (red ring)
6	Methylene Red Voges Proskauer test (MRVP)	+ for MR, -ve for VP
7	Simmons citrate Utilization test	-ve (green color)

B. Biofilm Assay

The results showed that all isolates were biofilm producers. Fourteen isolates were produced moderate biofilm in percentage (70%), while other six isolates were moderate biofilm producers in percentage (25%). As Demonstrated in table (2) and figure (1).

Table (2): The OD value and biofilm production result of *E. coli* isolates.

Isolate no.	OD1	OD2	OD3	Average	ODC	2*ODC	4*ODC	Type of biofilm
E 66	0.218	0.228	0.209	0.218	0.061	0.122	0.244	Moderate
E 96	0.243	0.266	0.25	0.253	0.061	0.122	0.244	Strong
E 75	0.248	0.218	0.221	0.229	0.061	0.122	0.244	moderate
E 89	0.237	0.159	0.168	0.188	0.061	0.122	0.244	moderate
E 51	0.233	0.179	0.17	0.194	0.061	0.122	0.244	moderate
E 90	0.233	0.195	0.212	0.213	0.061	0.122	0.244	moderate
E 103	0.245	0.221	0.16	0.208	0.061	0.122	0.244	moderate
E 55	0.231	0.169	0.187	0.195	0.061	0.122	0.244	moderate
E 54	0.252	0.217	0.245	0.238	0.061	0.122	0.244	moderate
E 1	0.335	0.206	0.236	0.259	0.061	0.122	0.244	Strong
E 72	0.206	0.166	0.191	0.187	0.061	0.122	0.244	Moderate
E 79	0.233	0.262	0.241	0.245	0.061	0.122	0.244	strong
E 91	0.18	0.167	0.161	0.169	0.061	0.122	0.244	Moderate
E 52	0.223	0.226	0.18	0.213	0.061	0.122	0.244	Moderate
E 2	0.194	0.244	0.21	0.216	0.061	0.122	0.244	Moderate
E 92	0.215	0.261	0.303	0.259	0.061	0.122	0.244	Strong
E 80	0.283	0.291	0.29	0.288	0.061	0.122	0.244	Strong
E 65	0.228	0.27	0.281	0.259	0.061	0.122	0.244	Strong
E 57	0.249	0.217	0.227	0.231	0.061	0.122	0.244	Moderate
E 71	0.207	0.223	0.271	0.233	0.061	0.122	0.244	Moderate



C. Effect of ZnO NPs Against Biofilm


Five *E. coli* isolates that gave highest OD value of biofilm production were selected from the 20 *E. coli* isolates (E92, E79, E80, E65 and E1) to show the effect of ZnONPs against pre-

mature and mature biofilm as listed in table (3), figure (2) and table (4), figure (3) respectively. The results showed that all concentrations of ZnONPs gave antibiofilm activity as premature biofilm against E.coli with different degrees incompare with control, table (3).

Table (3): The effect of ZnO NPs against pre-mature biofilm

Bacterial isolates	ZnO NPs concentrations (µg/ml)					LSD (P-value)
	Control	500	250	125	62.5	
E 92	0.259	0.061	0.055	0.054	0.056	0.044 * (0.046)
E 79	0.245	0.057	0.059	0.069	0.067	0.051 (0.039)
E 80	0.288	0.060	0.057	0.057	0.083	0.059 * (0.033)
E 65	0.259	0.066	0.058	0.055	0.062	0.051 * (0.038)
E 1	0.259	0.061	0.056	0.058	0.058	0.048 * (0.042)
LSD (P-value)	0.137 NS (0.874)	0.029 NS (0.891)	0.0252 NS (0.877)	0.0294 NS (0.763)	0.0257 NS (0.726)	---

* (P ≤0.05), NS: Non-Significant.




On the other hand, the current findings revealed that ZnO NPs were affected on mature biofilm of E.coli. The higher effect was achieved against bacterial isolates E79 and E65 by all concentrations, while there was no effect against bacterial isolates E92 and E1, table (4) and figure (3).

Table (4): The effect of ZnO NPs against mature biofilm

Bacterial isolates	ZnO NPs concentrations (µg/ml)					LSD (P-value)
	Control	500	250	125	62.5	
E 92	0.0684	0.108	0.26	0.40	0.117	0.317 * (0.049)
E 79	1.75	0.145	0.380	0.356	0.11	0.531 ** (0.0057)
E 80	0.288	0.088	0.301	0.191	0.101	0.283 NS (0.295)
E 65	1.121	0.147	0.296	0.104	0.096	0.569 ** (0.0006)
E 1	0.259	0.320	0.222	0.117	0.112	0.291 NS (0.602)
LSD (P-value)	0.549 ** (0.0078)	0.307 NS (0.118)	0.211 NS (0.703)	0.359 NS (0.065)	0.087 NS (0.794)	---

* (P ≤0.05), ** (P ≤0.01), NS: Non-Significant.



IV. DISCUSSION

UPEC are a causative agent in the great majority of UTIs, pyelonephritis, cystitis as well as infectious complications that can cause acute renal failure in both renal transplant patients and healthy individuals (34). UPEC expresses a wide range of virulence factors to overcome the mucosal barrier's inertia (35). When the UPEC breaches normally sterile urinary tract, the host's inflammatory responses are set off, which result in the production of cytokine, the infiltration of neutrophils and the exfoliation of infected bladder epithelial cells (36). When compare to other lactose fermenter bacteria, E. coli grow more readily on EMB agar which enhanced its proliferation. Large amount of lactose caused E. coli to produce extremely dark, metallic shiny colonies devoid of Klebsiella and Enterobacter (37). This could be because pink colonies didn't form as much acid accumulated (38,39). Recurrent and complicated UTIs are frequently caused by bacteria that form biofilm (40,41). Twenty off fifty urine specimen (or 40% from the total) were diagnosis as E. coli. Because it is the primary causative pathogen of approximately 80% of recurrent UTI in women, E. coli responsible for these infections (42). Ninety percent of UTIs caused by UPEC, which is colonize the faeces or perineal region and travel up the urinary tract to the bladder (43). Adhesins or fimbriae, siderophore systems, and toxins are among the distinct virulence factors that distinguish UPEC strains and are closely related with the colonization and persistence of bacteria in the urinary tract (44). In all 407 urine samples that were taken from patients at the University of Benin Teaching Hospital (UBTH), Benin, Edo State, Nigeria, who were either inpatient or outpatient and had suspected UTI. Male and female yield 162 (39.8%) and 245 (60.2%) E. coli isolates respectively (45). A total of 76 urine specimens were taken from of a patients who were experienced recurrent UTIs. After specimens underwent bacteriologically analysis, E. coli a counted for fifty (65.8%) of isolated bacterial strains. Using the microtiter plate assay, 100% of isolated UPEC strains showed a biofilm positive phenotype under optimal condition, 29 (58%) of these isolates categorized as weakly positive biofilm producers, and 21 (42%) categorized as highly positive biofilm producers (21). Antibacterial activity ZnO-NP against E. coli O157:H7 was discovered. As the ZnO-NP concentration rises the inhibitory effects also rise. The finding suggests that ZnO-NP may cause bacterial cell wall distortion and damage and this could lead to intracellular contents leaking out and ultimately the death of the bacterial (46). Depending on the nanoparticles concentrations, ZnO-NP exhibiting inhibitory effects on biofilm formation in UPEC isolates; these effects were more pronounced at MIC concentration than sub MIC concentrations dramatically reduced flu gene in UPEC isolates with strong biofilm but it is unable to prevent biofilm formation (11). According to the researches by Applerot et al (47) and Musarrat et al (48), ZnO-NP can dramatically reduce the amount of biofilm that form by E. coli strains. In their investigation, ZnO-NP had a stronger inhibitory effect than in one carried out by (11). This discrepancy results from the various approaches taken in the assessment of biofilm formation. Furthermore, size of nanoparticles and bacterial type are significant variables that could influence the nanoparticle's inhibitory effect. Smaller

particles have a stronger antibacterial effect because they have a larger surface area to volume ratio. Additionally, ZnO-NP inhibits *P. aeruginosa* from form biofilm and this may be useful in treatment of biofilm (49). The most likely mechanism for the bacterial cell ability to fight biofilms is that the nanoparticles treatment altered the permeability of their cell membranes, allowing nucleic acids to leak out of the cells (50).

CONCLUSION

From the previous results it was concluded that ZnO-NPs showed high activity against *E. coli* biofilm in both pre and post mature stage but the best effect was achieved against pre-mature one.

REFERENCES

1. Feng P, Weagant S and Grant M. Enumeration of *Escherichia coli* and the Coliform Bacteria. *Bacteriological Analytical Manual*. 8th ed. USA: FDA/Center for Food Safety & Applied Nutrition. 2007.
2. Batt C A. (2014). *Escherichia coli*, in: *Encyclopedia of Food Microbiology* (2nd Ed.). pp: 688-694.
3. Mohamad L S. The Effect of Alcoholic Extracts of *Zingiber officinale* Anti-*E. coli* Isolates Isolated from Urinary Tract Infection. *Iraqi Journal of Science*. 2019; 60(10): 2136-2140.
4. - Ramírez Castillo F Y, Guerrero Barrera A L, Harel J, Avelar González F J, Vogeleer P, et al., Biofilm Formation by *Escherichia coli* Isolated from Urinary Tract Infections from Aguascalientes, Mexico. *Microorganisms*, 2023; 11(12): 2858.
5. Yang X, Chen H, Zheng Y, Qu S, Wang H, Yi F. Disease burden and long-term trends of urinary tract infections: A worldwide report. *Front. Public Health*. 2022;10:888205.
6. Assafi M S, Ali F F, Polis R F, Sabaly N J, Qarani S M. An Epidemiological and Multidrug Resistance Study for *E. coli* Isolated from Urinary Tract Infection (Three Years of Study) *Baghdad Science Journal*. 2022; 19(1): 7-15.
7. Flores-Mireles A L, Walker J N, Caparon M, Hultgren S J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat Rev Microbiol*. 2015;13(5):269..
8. - Percival, S. L. and Williams, D. W. (2014). *Escherichia coli*: in *Microbiology of Waterborne Diseases* (2nd Ed.). pp: 89- 117.
9. Campbell N A, Reece J B. (2002). *Biology*. San Francisco: Pearson Education Inc.
10. Kaper J B, Nataro J P, Mobley H L. Pathogenic *Escherichia coli*. *Nat. Rev. Microbiol*. 2004; 2:123–140.
11. Foxman B. The epidemiology of urinary tract infection. *Nat. Rev. Urol*. 2010;7:653–660.
12. Ahmed D A, Khalaf Z Z , Obaid H H. Comparative study of antibiofilm activity of Lime juice and Lithium dioxide nanoparticles against *E. coli* isolated from local made cheese. *Journal of University of Shanghai for Science and Technology*. 2021, 23 (11): 297-311.
13. Li D, Li P, Yu X, Zhang X, Guo Q, et al. Molecular Characteristics of *Escherichia coli* Causing Bloodstream Infections During 2010–2015 in a Tertiary Hospital, Shanghai, China. *Infect Drug Resist*. 2021;14: 2079-2086.
14. Abed Z A, Habib K A, Abass Z N. Genotypic Study of Two Virulence Factors *fimH* and *kpsMTII* in Uropathogenic *Escherichia coli* Isolates from Children Patients with Urinary Tract Infections *Baghdad Science Journal*. 2014;11(4): 1475-1480.
15. Katongole P, Nalubega F, Florence N C, et al. Biofilm formation, antimicrobial susceptibility and virulence genes of Uropathogenic *Escherichia coli* isolated from clinical isolates in Uganda. *BMC Infect Dis*. 2020; 20, 453.
16. Mittal S, Sharma M, Chaudhary U. Biofilm and multidrug resistance in uropathogenic *Escherichia coli*. *Pathog. Glob. Health*. 2015;109:26–29.
17. Wu D, Ding Y, Yao K, Gao W, Wang Y. Antimicrobial Resistance Analysis of Clinical *Escherichia coli* Isolates in Neonatal Ward. *Front. Pediatr*. 2021; 9:1-7.
18. Al-Hasnawy H H, Judi M R, Hamza H J. The Dissemination of Multidrug Resistance (MDR) and Extensively Drug Resistant (XDR) among Uropathogenic *E. coli* (UPEC) Isolates from Urinary Tract Infection Patients in Babylon Province, Iraq. *Baghdad Science Journal*. 2019; 16 (4): 986-992.
19. Hammadi A H, Yaseen N N, Al-Mathkhury H J. F. Molecular Detection of Some β -lactamases Genes in Uropathogenic *Escherichia coli*. *Iraqi Journal of Science*. 2015; 56 (3A): 1925-1931.
20. Sharma G, Sharma S, Sharma P, Chandola D, Dang S, Gupta S, Gabrani R. *Escherichia coli* biofilm: development and therapeutic strategies. *J Appl Microbiol*. 2016; 121(2):309-19.
21. Ebraheem A A, Alwendawi Sh A. Screening for in Vitro Biofilm Formation Ability of Locally Isolated Uropathogenic *Escherichia coli* (UPEC) *Iraqi Journal of Science*. 2015; 56(2B): 1310-1314.
22. Ali S A, Al-Dahmoshi H O M. Detection of Efflux Pumps Gene and Relation with Antibiotics Resistance in Uropathogenic *Escherichia coli* (UPEC) Isolated from Patients with Cystitis *Iraqi Journal of Science*, 2022; 63(6): 2388-2397.
23. Terlizzi M E, Gribaudo G, Maffei M E. UroPathogenic *Escherichia coli* (UPEC) infections: virulence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies. *Front Microbiol*. 2017; 8:1566.
24. Khalaf Z Z, Flayyih M T. Detection of *cnf1* and *cnf2* genes in clinical isolates of *E. coli*. *The Egyptian journal of Hospital Medicine*, 2022; 89(2): 8088-8094.
25. Shakerimoghaddam A, Ghaemi E A, Jamali A. Zinc oxide nanoparticle reduced biofilm formation and antigen 43 expressions in uropathogenic *Escherichia coli*. *Iran J Basic Med Sci*. 2017; 20(4):451-456.
26. Al-mawlawi Z S, Obaid H H. Antibacterial Activity of Synergistic Effect of Colicin and Gold Nanoparticles Against *Pseudomonas Aeruginosa*. *Iraqi Journal of Science*, 2017; 58(2C): 1020-1027.
27. Shrestha A, Zhilong S, Gee NK, Kishen A. Nanoparticulates for antibiofilm treatment and effect of aging on its antibacterial activity. *J Endod* 2010; 36:1030-1035.
28. Mukane L, Racenis K, Rezevska D, Petersons A, Kroica J. Anti-Biofilm Effect of Bacteriophages and Antibiotics against Uropathogenic *Escherichia coli*. *Antibiotics (Basel)*. 2022; 11(12):1706.
29. Cheesbrough M (1985). *Medical laboratory manual for tropical countries*. Vol. II. Microbiology. pp. 400-480.
30. Flournoy D J, Wongpradit S, Silberg S L. Facilitating Identification of Lactose-Fermenting Enterobacteriaceae on MacConkey Agar. *Proc. Okla. Acad. Sci*. 1990; 70: 5-8.

31. Stepanovic S, Vukovic D, Hola V, Di Bonaventura G, Djukic S, et al. Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. *APMIS*. 2007; 115:891– 899.
32. Ansari M A, Haris M K, Aijaz A K, Asfia S, Ameer A. Synthesis and characterization of the antibacterial potential of ZnO nanoparticles against extended spectrum *b*-lactamases-producing *E.coli* and *K. pneumoniae* isolated from a tertiary care hospital of North India. *Appl.Microbiol. Biotech.*, 2009; (10): 3733–3736.
33. SAS. (2018). *Statistical Analysis System, User's Guide. Statistical. Version 9.6th ed.* SAS. Inst. Inc. Cary. N.C. USA.
34. Bien J, Sokolova O, Bozko P. Role of Uropathogenic *Escherichia coli* Virulence Factors in Development of Urinary Tract Infection and Kidney Damage. *Int J Nephrol*. 2012;2012:681473.
35. Wang L, Hu C, Shao L. The antimicrobial activity of nanoparticles: present situation and prospects for the future. *Int J Nanomed*. 2017;12:1227.
36. Hernández-Chiñas U, Ahumada-Cota R E, Navarro-Ocaña A, Chávez-Berrocal M E, Molina-López J, et al. Phenotypic and genotypic characteristics of *Escherichia coli* strains isolated during a longitudinal follow-up study of chronic urinary tract infections. *Frontiers in public health*, 2023; 11, 1240392.
37. Lee R, Hass N P, Kollitz A, Wilson M. The Prevalence of Urinary Tract Infections and Antibiotic Prescription Treatments Across Three Countries: A Retrospective Study Using an Electronic Medical Record. *Cureus*, 2023; 15(10), e46466.
38. Isali I, Wong T R, Batur A F, Wu C W, Schumacher F R, et al. Recurrent urinary tract infection genetic risk: a systematic review and gene network analysis. *International urogynecology journal*, 2023; 10.1007/s00192-023-05671-6. Advance online publication.
39. Merchant I A, Packer R A. *Veterinary Bacteriology and Virology*. 7th ed., The Iowa State University Press, Ames, Iowa, USA. 1969, pp: 211-305.
40. Dash D, Sarangi G, Patro P, Chayani N. Study of biofilm production in *Escherichia coli* causing urinary tract infection and its correlation with antimicrobial resistance. *J Acad Clin Microbiol*. 2018; 20 (2):88.
41. Echols R M, Tosiello R L, Haverstock D C, Tice A D. Demographic, clinical and treatment parameters influencing the outcome of acute cystitis. *Clin. Infect. Dis*.1999; 29:113–9.
42. Carter G R. *Essentials of Veterinary Bacteriology and Mycology*. 3rd ed. 1986, pp: 312-330.
43. Stapleton A. Novel mechanism of *P*-fimbriated *Escherichia coli* virulence in pyelonephritis. *J. Am. Soc .Nephrol*. 2005, 16: 3458– 60.
44. Momoh A R M, Orhue P O, Idonije O B, Oaikhena A G, Nwoke E O, Momoh A A. The antibiogram types of *Escherichia coli* isolated from suspected urinary tract infection samples. *J. Microbiol. Biotech. Res*. 2011;1 (3): 57-65.
45. Liu Y, He L, Mustapha A, Li H, Hu Z Q, Lin M. Antibacterial activities of zinc oxide nanoparticles against *Escherichia coli* O157:H7. *Journal of applied microbiology*. 2009; 107(4): 1193–1201.
46. Applerot G, Lellouche J, Perkash N, Nitzan Y, Gedanken A, Banin E. ZnO nanoparticle-coated surfaces inhibit bacterial biofilm formation and increase antibiotic susceptibility. *Rsc Adv* ,2012, 2: 2314-2321.
47. Musarrat J, Ansari A K, Saquib Q, Siddiqui M, Khan S, et al. Green Synthesis of nanoparticles and their role as nano-antibiotics and anti-biofilm agents. *Planta Med*. 2015; 81:OA44.
48. Valadbeigi H, Sadeghifard N, Kaviar V H. et al. Effect of ZnO nanoparticles on biofilm formation and gene expression of the toxin-antitoxin system in clinical isolates of *Pseudomonas aeruginosa*. *Ann Clin Microbiol Antimicrob*. 2023; 22(89).
49. Kaur T, Putatunda C, Vyas A, Kumar G. Zinc oxide nanoparticles inhibit bacterial biofilm formation via altering cell membrane permeability. *Preparative biochemistry & biotechnology*. 2021; 51(4), 309–319.